Introduction Despite representing only 3% of the US population, immunocompromised (IC)
individuals account for nearly half of the COVID-19 breakthrough hospitalizations. IC …

Approximately 3% of US adults are immunocompromised and less capable of fighting
infections such as SARS-CoV-2 (the causative agent of COVID-19). Individuals may be …

Background: Considering the indeterminate effects following the administration of three
doses of the SARS-CoV-2 vaccine to patients under dialysis, the present study aimed to …

Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …

Background Humoral and cellular immune responses are known to be crucial for patients to
recover from COVID-19 and to protect them against SARS-CoV-2 reinfection once infected …

The anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients
with B-cell malignancies were examined in a real-world setting. A next-generation …

Introduction This study examines the efficacy and safety of three COVID-19 booster vaccines
including mRNA-based vaccines (BNT162b2 (BioNTech/Pfizer) and/or mRNA-1273 …

Purpose of review: To review the data on the immunogenicity of COVID-19 vaccines,
administered by different strategies, in solid organ transplant recipients (SOTRs). Recent …

Methods A pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50
or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes …

Background Vaccination has proven the potential to control the COVID-19 pandemic
worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV …